Company intelligence / Profile preview

DHS Tar

Ownership: Private
Development stage: Other

Overview

DHS Tar is a biotechnology company focused on the development of novel therapeutic agents targeting the sphingolipid metabolic pathway. The company's primary research centers on dihydrosphingosine (DHS) and its role in cellular signaling related to oncology and inflammatory diseases. By modulating these lipid-based targets, DHS Tar aims to create precision medicines that address unmet needs in complex disease states. The company is currently in the pre-clinical stage, advancing its lead candidates through early-stage validation and optimization.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on DHS Tar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DHS Tar.

Explore the full profile